Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols

Wafaa Alabsi, Basanth Babu Eedara, David Encinas-Basurto, Robin Polt, Heidi M. Mansour

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

Central nervous system (CNS) disorders, such as psychiatric disorders, neurodegeneration, chronic pain, stroke, brain tumor, spinal cord injury, and many other CNS diseases, would hugely benefit from specific and potent peptide pharmaceuticals and their low inherent toxicity. The delivery of peptides to the brain is challenging due to their low metabolic stability, which decreases their duration of action, poor penetration of the blood-brain barrier (BBB), and their incompatibility with oral administration, typically resulting in the need for parenteral administration. These challenges limit peptides’ clinical application and explain the interest in alternative routes of peptide administration, particularly nose-to-brain (N-to-B) delivery, which allows protein and peptide drugs to reach the brain noninvasively. N-to-B delivery can be a convenient method for rapidly targeting the CNS, bypassing the BBB, and minimizing systemic exposure; the olfactory and trigeminal nerves provide a unique pathway to the brain and the external environment. This review highlights the intranasal delivery of drugs, focusing on peptide delivery, illustrating various clinical applications, nasal delivery devices, and the scope and limitations of this approach.

Original languageEnglish (US)
Article number1870
JournalPharmaceutics
Volume14
Issue number9
DOIs
StatePublished - Sep 2022

Keywords

  • blood-brain barrier (BBB)
  • central nervous system (CNS)
  • dry powders
  • intranasal delivery
  • nasal devices
  • nebulization
  • peptides

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols'. Together they form a unique fingerprint.

Cite this